Larson Financial Group LLC cut its position in shares of Danaher Co. (NYSE:DHR – Free Report) by 21.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,171 shares of the conglomerate’s stock after selling 582 shares during the period. Larson Financial Group LLC’s holdings in Danaher were worth $498,000 at the end of the most recent reporting period.
A number of other large investors have also modified their holdings of the company. Heck Capital Advisors LLC acquired a new position in shares of Danaher in the 4th quarter valued at $27,000. Decker Retirement Planning Inc. bought a new stake in Danaher in the fourth quarter valued at about $31,000. Golden State Wealth Management LLC acquired a new position in Danaher in the fourth quarter worth about $31,000. Teachers Insurance & Annuity Association of America bought a new position in Danaher during the third quarter worth about $39,000. Finally, MidAtlantic Capital Management Inc. acquired a new stake in Danaher during the third quarter valued at approximately $40,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.
Danaher Stock Down 1.1 %
Shares of NYSE:DHR opened at $212.35 on Monday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. The stock has a market cap of $151.77 billion, a price-to-earnings ratio of 40.22, a P/E/G ratio of 2.66 and a beta of 0.82. The company has a 50 day moving average of $222.51 and a 200-day moving average of $242.62. Danaher Co. has a one year low of $196.80 and a one year high of $281.70.
Danaher Increases Dividend
The business also recently announced a quarterly dividend, which will be paid on Friday, April 25th. Shareholders of record on Friday, March 28th will be paid a $0.32 dividend. This is a positive change from Danaher’s previous quarterly dividend of $0.27. The ex-dividend date is Friday, March 28th. This represents a $1.28 annualized dividend and a yield of 0.60%. Danaher’s dividend payout ratio is presently 24.24%.
Wall Street Analysts Forecast Growth
Several research firms recently commented on DHR. Bank of America upgraded Danaher from a “neutral” rating to a “buy” rating and set a $290.00 target price for the company in a research report on Friday, December 13th. Guggenheim initiated coverage on Danaher in a report on Thursday, December 19th. They set a “buy” rating and a $275.00 price objective for the company. JPMorgan Chase & Co. lowered their target price on shares of Danaher from $310.00 to $300.00 and set an “overweight” rating on the stock in a report on Tuesday, January 28th. Jefferies Financial Group cut their price target on shares of Danaher from $285.00 to $260.00 and set a “buy” rating for the company in a report on Wednesday, January 29th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $277.00 price objective (down from $299.00) on shares of Danaher in a research note on Thursday, January 30th. Seven equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $278.00.
Get Our Latest Stock Analysis on DHR
Insider Transactions at Danaher
In related news, SVP Brian W. Ellis sold 5,700 shares of the stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the sale, the senior vice president now directly owns 20,230 shares in the company, valued at $4,534,149.90. This trade represents a 21.98 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 11.10% of the company’s stock.
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Featured Articles
- Five stocks we like better than Danaher
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Institutional Investors Bet $1B on These 4 Stocks—Should You?
- Are Penny Stocks a Good Fit for Your Portfolio?
- One Must-Buy Stock and One to Avoid as Tariffs Shake the Market
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.